Fisher Asset Management LLC Acquires 8,012 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Fisher Asset Management LLC lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 6.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 124,399 shares of the company's stock after acquiring an additional 8,012 shares during the quarter. Fisher Asset Management LLC owned approximately 0.40% of Medpace worth $41,524,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. Renaissance Technologies LLC increased its position in shares of Medpace by 38.3% during the second quarter. Renaissance Technologies LLC now owns 443,588 shares of the company's stock valued at $182,692,000 after buying an additional 122,800 shares during the period. Clearbridge Investments LLC raised its holdings in Medpace by 55.1% in the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company's stock worth $166,343,000 after purchasing an additional 143,481 shares in the last quarter. Westwind Capital lifted its position in Medpace by 800.1% during the second quarter. Westwind Capital now owns 380,929 shares of the company's stock valued at $156,886,000 after buying an additional 338,610 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Medpace by 62.3% during the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company's stock valued at $127,941,000 after buying an additional 119,257 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Medpace by 1.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 256,100 shares of the company's stock worth $103,504,000 after buying an additional 3,222 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $335.21 on Wednesday. The stock's 50-day simple moving average is $339.37 and its two-hundred day simple moving average is $372.21. The stock has a market capitalization of $10.42 billion, a price-to-earnings ratio of 29.35, a PEG ratio of 1.87 and a beta of 1.37. Medpace Holdings, Inc. has a 52-week low of $268.80 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The business had revenue of $533.32 million for the quarter, compared to analysts' expectations of $540.99 million. During the same quarter last year, the company posted $2.22 EPS. The company's revenue was up 8.3% compared to the same quarter last year. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several research reports. Robert W. Baird boosted their price objective on shares of Medpace from $349.00 to $354.00 and gave the stock a "neutral" rating in a research note on Monday. Baird R W cut Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. StockNews.com lowered Medpace from a "buy" rating to a "hold" rating in a research report on Friday, September 27th. Redburn Atlantic initiated coverage on Medpace in a report on Monday, October 14th. They issued a "buy" rating and a $404.00 target price on the stock. Finally, UBS Group downgraded Medpace from a "buy" rating to a "neutral" rating and reduced their price target for the company from $420.00 to $350.00 in a report on Friday, September 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Medpace presently has a consensus rating of "Hold" and an average target price of $380.56.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.